288 related articles for article (PubMed ID: 10726657)
1. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
Traidej M; Chen L; Yu D; Agrawal S; Chen J
Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
[TBL] [Abstract][Full Text] [Related]
2. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.
Hengstermann A; Linares LK; Ciechanover A; Whitaker NJ; Scheffner M
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1218-23. PubMed ID: 11158620
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
[TBL] [Abstract][Full Text] [Related]
4. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
Camus S; Higgins M; Lane DP; Lain S
FEBS Lett; 2003 Feb; 536(1-3):220-4. PubMed ID: 12586367
[TBL] [Abstract][Full Text] [Related]
5. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.
Goodwin EC; DiMaio D
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12513-8. PubMed ID: 11070078
[TBL] [Abstract][Full Text] [Related]
6. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells.
Beer-Romero P; Glass S; Rolfe M
Oncogene; 1997 Feb; 14(5):595-602. PubMed ID: 9053858
[TBL] [Abstract][Full Text] [Related]
7. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
8. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation.
Cheng YW; Wu MF; Wang J; Yeh KT; Goan YG; Chiou HL; Chen CY; Lee H
Cancer Res; 2007 Nov; 67(22):10686-93. PubMed ID: 18006810
[TBL] [Abstract][Full Text] [Related]
10. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells.
Huang H; Huang SY; Chen TT; Chen JC; Chiou CL; Huang TM
J Cell Biochem; 2004 Mar; 91(4):756-65. PubMed ID: 14991767
[TBL] [Abstract][Full Text] [Related]
12. HPV-16 E6 and E7 oncogene expression is downregulated as a result of Mdm2 knockdown.
Diaz D; Santander MA; Chavez JA
Int J Oncol; 2012 Jul; 41(1):141-6. PubMed ID: 22504553
[TBL] [Abstract][Full Text] [Related]
13. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.
Scheffner M; Huibregtse JM; Vierstra RD; Howley PM
Cell; 1993 Nov; 75(3):495-505. PubMed ID: 8221889
[TBL] [Abstract][Full Text] [Related]
14. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
15. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.
Freedman DA; Levine AJ
Mol Cell Biol; 1998 Dec; 18(12):7288-93. PubMed ID: 9819415
[TBL] [Abstract][Full Text] [Related]
16. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
Honda R; Tanaka H; Yasuda H
FEBS Lett; 1997 Dec; 420(1):25-7. PubMed ID: 9450543
[TBL] [Abstract][Full Text] [Related]
17. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
Hoppe-Seyler F; Butz K
J Virol; 1993 Jun; 67(6):3111-7. PubMed ID: 8388491
[TBL] [Abstract][Full Text] [Related]
18. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
19. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
20. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
